Biofrontera AG Stock price

Equities

B8F

DE0006046113

Pharmaceuticals

Delayed Xetra 12:06:06 2024-03-28 pm EDT 5-day change 1st Jan Change
0.33 EUR -4.90% Intraday chart for Biofrontera AG -2.65% -17.71%
Sales 2021 28.79M 31.08M Sales 2022 25.74M 27.79M Capitalization 97.31M 105M
Net income 2021 38M 41.03M Net income 2022 -44M -47.51M EV / Sales 2021 2.79 x
Net cash position 2021 3.61M 3.9M Net cash position 2022 4.88M 5.26M EV / Sales 2022 3.59 x
P/E ratio 2021
2.18 x
P/E ratio 2022
-1.98 x
Employees 92
Yield 2021 *
-
Yield 2022
-
Free-Float 29.74%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.44%
1 week+15.28%
Current month-2.25%
1 month+1.17%
3 months-14.95%
6 months-36.91%
Current year-13.47%
More quotes
1 week
0.31
Extreme 0.31
0.35
1 month
0.30
Extreme 0.3
0.42
Current year
0.30
Extreme 0.3
0.58
1 year
0.30
Extreme 0.3
1.30
3 years
0.30
Extreme 0.3
3.17
5 years
0.30
Extreme 0.3
8.07
10 years
0.30
Extreme 0.3
8.07
More quotes
Managers TitleAgeSince
Director of Finance/CFO 55 22-09-11
Public Communications Contact - -
Members of the board TitleAgeSince
Chairman 63 21-12-13
Director/Board Member - 21-12-13
Director/Board Member 47 21-12-13
More insiders
Date Price Change Volume
24-03-28 0.33 -4.90% 14 426
24-03-27 0.347 +1.46% 11,628
24-03-26 0.342 0.00% 4,887
24-03-25 0.342 0.00% 1,500
24-03-22 0.342 +0.88% 100

Delayed Quote Xetra, March 28, 2024 at 04:02 am EDT

More quotes
Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Biofrontera AG - Xetra